Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 35.08M 25.48M 21.83M 20.42M 18.69M 2.44B 35.55M 241M 94.09M 1.22B 95.67M 93.59M 4.05B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 34.85M 25.31M 21.68M 20.29M 18.57M 2.42B 35.31M 240M 93.47M 1.22B 95.04M 92.98M 4.02B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
08-10 Voyageur Pharmaceuticals Ltd. Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing CI
07-24 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2026 CI
06-18 Voyageur Pharmaceuticals Evaluates Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility CI
06-10 Voyageur Pharmaceuticals Ltd Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support At Frances Creek Barite Project CI
06-04 Voyageur Pharmaceuticals Ltd. announced that it has received CAD 5.005278 million in funding CI
04-30 Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 10 million in funding CI
04-30 Voyageur Pharmaceuticals Ltd. cancelled the transaction announced on March 24, 2026 CI
04-24 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 28, 2026 CI
03-27 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2025 CI
03-26 Voyageur Pharmaceuticals Ltd. Auditor Raises 'Going Concern' Doubt CI
03-23 Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 7.5 million in funding CI
03-04 Voyageur Pharmaceuticals Ltd. Announces Independent Laboratory Test Results for Its Barium Sulfate Active Pharmaceutical Ingredient CI
02-23 Voyageur Pharmaceuticals Announces Collaboration with Bayer Aktiengesellschaft CI
Current month+25.00%
1 month+9.09%
3 months+99.34%
6 months+9.09%
Current year-7.76%
1 week 0.12
Extreme 0.12
0.12
1 month 0.1
Extreme 0.096
0.13
Current year 0.01
Extreme 0.014
0.2
1 year 0
Extreme 0.0033
0.2
3 years 0
Extreme 0.0005
0.25
5 years 0
Extreme 0.0005
0.25
10 years 0
Extreme 0.0005
0.25
Manager TitleAgeSince
Chief Executive Officer - 30/06/2019
Director of Finance/CFO - 16/08/2022
Chief Tech/Sci/R&D Officer - 16/09/2024
Director TitleAgeSince
Director/Board Member - 05/12/2017
Director/Board Member - 30/06/2019
Chairman - 29/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 25.48M
+0.88%+6.38%+76.86%+128.23% 1,119B
+1.07%+3.80%+51.03%+61.48% 651B
+1.20%+6.21%+26.47%+76.45% 468B
+1.02%+5.77%+43.09%+47.70% 374B
+0.85%+4.07%+23.88%+41.58% 302B
+1.26%+6.81%+1.59%+14.67% 259B
+1.88%+5.81%+48.54%+68.52% 238B
+1.59%+2.09%-15.52%-52.29% 208B
+1.87%+5.61%+25.81%+92.42% 181B
Average +1.16%+4.97%+31.31%+53.20% 422.21B
Weighted average by Cap. +1.14%+5.09%+44.31%+72.55%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.81 0.01 0.08 0.03 0.41 0.03 0.03 1.35
Net income -1.71M -1.24M -1.06M -994K -910K -119M -1.73M -11.74M -4.58M -59.6M -4.66M -4.55M -197M -3.53M -2.57M -2.2M -2.06M -1.88M -245M -3.58M -24.29M -9.47M -123M -9.63M -9.42M -408M
Net Debt -113K -81.8K -70.07K -65.56K -60.02K -7.83M -114K -775K -302K -3.93M -307K -300K -13M -231K -167K -143K -134K -123K -16.02M -234K -1.59M -618K -8.05M -629K -615K -26.62M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
19/08/26 US$0.1200 0.00% 100,000
17/08/26 US$0.1200 0.00% 70,500
14/08/26 US$0.1200 0.00% 17,000
13/08/26 US$0.1200 0.00% 14,000

Annual profits - Rate of surprise